Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary.
R. Corre
No relevant relationships to disclose
C. Chouaid
Consultant or Advisory Role - Amgen; Lilly; Roche
Honoraria - Amgen; GlaxoSmithKline; Lilly; Roche
Research Funding - Amgen; Roche
F. Barlesi
Consultant or Advisory Role - Roche
Research Funding - Roche
H. Le Caer
Honoraria - Lilly
E. Dansin
Honoraria - Lilly; Roche
A. Vergnenegre
Honoraria - AstraZeneca; Lilly; Roche
P. Fournel
Honoraria - Lilly; Roche